Evommune (NYSE:EVMN) Given New $65.00 Price Target at HC Wainwright

Evommune (NYSE:EVMN) had its price target hoisted by HC Wainwright from $35.00 to $65.00 in a research note issued to investors on Tuesday, Marketbeat reports. HC Wainwright currently has a buy rating on the stock.

A number of other research firms have also weighed in on EVMN. Zacks Research raised Evommune to a “hold” rating in a research note on Tuesday, December 2nd. Leerink Partners assumed coverage on shares of Evommune in a research report on Monday, December 1st. They set an “outperform” rating and a $42.00 price target for the company. Weiss Ratings started coverage on shares of Evommune in a report on Tuesday, February 3rd. They issued a “sell (e)” rating on the stock. Oppenheimer initiated coverage on shares of Evommune in a research note on Thursday, January 22nd. They set an “outperform” rating and a $42.00 price objective for the company. Finally, Raymond James Financial initiated coverage on shares of Evommune in a report on Wednesday, January 7th. They set a “strong-buy” rating and a $40.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.71.

Evommune Stock Up 70.7%

Shares of NYSE:EVMN opened at $29.00 on Tuesday. The company has a market capitalization of $914.08 million and a PE ratio of -3.59. The company’s 50-day moving average is $18.57. Evommune has a 12-month low of $13.89 and a 12-month high of $33.20.

Evommune (NYSE:EVMN) last released its earnings results on Thursday, December 11th. The company reported ($8.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.58) by ($1.49). The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $10.00 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Capricorn Fund Managers Ltd bought a new position in shares of Evommune in the 4th quarter worth approximately $1,027,000. China Universal Asset Management Co. Ltd. bought a new position in Evommune in the fourth quarter worth $34,000. Sectoral Asset Management Inc. purchased a new position in Evommune during the fourth quarter valued at $10,084,000. Geode Capital Management LLC purchased a new position in Evommune during the fourth quarter valued at $1,881,000. Finally, Seven Grand Managers LLC bought a new stake in shares of Evommune during the 4th quarter valued at $1,284,000.

Evommune News Roundup

Here are the key news stories impacting Evommune this week:

• Positive Sentiment: Phase 2a proof‑of‑concept trial: EVO301 met its primary endpoint in a randomized, double‑blind Phase 2a in moderate‑to‑severe atopic dermatitis — the core catalyst behind the rally. Evommune Announces Positive Top-line Data
• Positive Sentiment: Evercore ISI raised its price target to $55 following the positive data, signaling increased analyst confidence in EVO301’s value and upside potential. Objectif de cours d’Evommune relevé à 55$ par Evercore ISI
• Positive Sentiment: HC Wainwright raised its price target sharply (from $35 to $65) and maintains a Buy rating, further reinforcing bullish analyst sentiment and likely contributing to buying pressure. EVMN price target raised by HC Wainwright
• Neutral Sentiment: Market reaction: the stock traded with very high volume and moved well above its 50‑day moving average, reflecting short‑term repositioning by investors; this spike could attract additional momentum traders but also increase volatility.
• Negative Sentiment: Fundamentals/risks remain: Evommune is still a clinical‑stage biotech (negative trailing EPS and prior quarterly EPS miss), so commercialization, regulatory approval, and further trial data remain material risks that could reverse gains.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.